

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Baricitinib for treating moderate to severe atopic dermatitis ID1622

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

It is possible that the assessment tools for assessing the severity of atopic dermatitis and the response to treatment may not be sensitive enough in people with some skin colours. This should be explored with the clinical experts at the committee meeting.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Skin colour has been added as a subgroup.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Nicole Elliott
Date: 16/04/2020